

Remarks

Currently Claims 11, 15 and 25, 26 and 28 are pending. Claim 27 is canceled herein, without prejudice. Applicants expressly reserve the right to file one or more continuation applications directed toward the subject matter of claim 27. No new matter is added. Entry of the foregoing amendment is respectfully requested.

Applicants acknowledge with appreciation the allowance of claims 11, 15, 25, 26 and 28. While Applicants do not agree with the rejection of claim 27, the claim is cancelled for the purpose of expediting grant of a patent on the now claimed subject matter. The rejection is moot in view of the cancellation of claim 27.

All outstanding rejections having been resolved, Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 16 July 2008
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@gsk.com